12,006 Shares in Phreesia, Inc. (NYSE:PHR) Acquired by PharVision Advisers LLC

PharVision Advisers LLC bought a new position in shares of Phreesia, Inc. (NYSE:PHR - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 12,006 shares of the company's stock, valued at approximately $302,000.

Several other institutional investors and hedge funds have also made changes to their positions in PHR. Barclays PLC boosted its holdings in Phreesia by 83.6% in the third quarter. Barclays PLC now owns 94,929 shares of the company's stock valued at $2,163,000 after purchasing an additional 43,225 shares during the last quarter. Wesbanco Bank Inc. boosted its stake in shares of Phreesia by 76.9% during the 4th quarter. Wesbanco Bank Inc. now owns 46,000 shares of the company's stock valued at $1,157,000 after buying an additional 20,000 shares during the last quarter. R Squared Ltd acquired a new stake in shares of Phreesia during the fourth quarter worth approximately $30,000. Rhumbline Advisers grew its position in shares of Phreesia by 7.4% during the fourth quarter. Rhumbline Advisers now owns 83,631 shares of the company's stock worth $2,104,000 after buying an additional 5,756 shares in the last quarter. Finally, Venturi Wealth Management LLC bought a new stake in shares of Phreesia in the fourth quarter worth $76,000. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

Phreesia Trading Up 2.3%

Shares of Phreesia stock traded up $0.54 on Tuesday, reaching $24.60. 148,348 shares of the company were exchanged, compared to its average volume of 437,969. The stock has a fifty day moving average price of $25.08 and a 200-day moving average price of $25.24. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of -16.73 and a beta of 0.74. Phreesia, Inc. has a fifty-two week low of $17.07 and a fifty-two week high of $30.53.

Insider Buying and Selling at Phreesia

In other Phreesia news, COO Evan Roberts sold 7,233 shares of Phreesia stock in a transaction on Tuesday, April 8th. The shares were sold at an average price of $23.85, for a total transaction of $172,507.05. Following the completion of the sale, the chief operating officer now owns 776,652 shares of the company's stock, valued at $18,523,150.20. This trade represents a 0.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Balaji Gandhi sold 1,827 shares of the business's stock in a transaction on Wednesday, March 26th. The shares were sold at an average price of $27.46, for a total transaction of $50,169.42. Following the transaction, the chief financial officer now owns 103,591 shares in the company, valued at approximately $2,844,608.86. This represents a 1.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 42,474 shares of company stock valued at $1,023,208 in the last 90 days. 5.80% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

PHR has been the subject of a number of research reports. Needham & Company LLC reiterated a "buy" rating and issued a $29.00 price target on shares of Phreesia in a research note on Thursday, March 13th. Wall Street Zen lowered Phreesia from a "buy" rating to a "hold" rating in a research report on Saturday. KeyCorp dropped their price target on Phreesia from $30.00 to $28.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 16th. Canaccord Genuity Group lifted their price objective on shares of Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a report on Thursday, March 13th. Finally, DA Davidson dropped their price objective on shares of Phreesia from $36.00 to $34.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $31.33.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.